preloader
preloader

Harnessing AI for Strategic Market Assessment Post-Loss of Exclusivity (LOE) in 2025

  • Client

    A leading pharmaceutical company specialising in anti-infective treatments, with a key product facing Loss of Exclusivity (LOE) in 2025. The client operates in both hospital and retail segments and sought advanced, data-driven strategies to sustain market share and profitability post-LOE.
  • Primary Goal

    Conduct a comprehensive market analysis post-LOE to evaluate competitors, pricing shifts, and buyer behaviour, leveraging AI-driven insights for analog selection, strategic positioning, and resource optimisation to safeguard market share, maintain pricing integrity, and enhance decision-making efficiency.

  • Vamstar Capability

    • Enhanced Insights

    • AI Price Optimisation

    • Competitor Analysis

    • Margins Protection

Introduction

Facing the 2025 Loss of Exclusivity (LOE) for a flagship anti-infective product, a leading pharmaceutical company required robust insights into post-LOE market dynamics. The product, a vital treatment sold across hospital and retail segments, faced significant pricing and competitive pressures.

 

Vamstar employed its proprietary AI to analyse market trends, competitor strategies, and buyer behaviours. This involved leveraging vast datasets and AI algorithms to provide actionable strategic options and defend market share effectively.

 

The client expected precise, data-backed recommendations to mitigate risks, optimise resource allocation, and refine competitive strategies, ensuring sustained profitability and market presence.

Key outcomes

  • Enhanced Insights: Comprehensive post-LOE market analysis

  • AI Optimisation: Precision in pricing and strategy modelling

  • Competitor Analysis: Identification of key threats and opportunities

  • Resource Efficiency: Data-driven allocation of commercial efforts

  • Sustained Margins: Minimised erosion through strategic pricing

Transformation Journey

  • Before Vamstar
  • During Vamstar’s Involvement
  • After Vamstar

The pharmaceutical company grappled with a legacy approach to market assessment, heavily reliant on traditional consulting firms. These firms provided narrow, human-only analyses that lacked scalability, precision, and data depth. Market intelligence was fragmented, with analogue selection processes based on subjective judgment rather than comprehensive data.

This approach led to significant inefficiencies: analogue selection was slow, missed critical competitive signals, and often failed to align with real-world market dynamics. Insights were reactive, offering limited strategic value, and left the company vulnerable to competitive pressures and rapid pricing erosion.

The lack of predictive analytics and forward-looking strategies created a strategic blind spot, impeding the company’s ability to effectively address post-LOE challenges and sustain its market position.

Harness AI to drive growth

Take a step towards improving your commercial operations, Register today